부산대학교 도서관

INTRODUCTION: The impact of adjuvant chemotherapy (ACT) using regimens including gemcitabine and platinum on the improvement of the prognosis of patients with locally advanced upper tract urothelial carcinoma (UTUC) has been recently demonstrated. This study aimed to determine the utility of ACT for patients with locally advanced UTUC in real-world clinical practice and the differences in efficacy among regimens. METHODS: Of 206 UTUC patients who underwent radical nephroureterectomy, 78 were pathologically diagnosed as T3 or higher and/or had pathologically identified lymph node metastasis; 36 in the ACT group and 42 in the non-ACT group were evaluated for patient background, recurrence, and prognosis. In the ACT group, either cisplatin (GC group, 12 cases) or carboplatin (GCa group, 24 cases) was administered as the platinum agent to be combined with gemcitabine. RESULT: The median patient age in the ACT group and that in the non-ACT group was 71 and 79 years, respectively (p CONCLUSIONS: In real-world clinical practice in Japan, UTUC patients who receive ACT after radical nephroureterectomy may be expected to have better cancer control than those who do not receive ACT.
INTRODUCTION Upper tract urothelial carcinoma (UTUC) is a relatively rare malignant disease compared with bladder cancer, and it accounts for 5-10% of urothelial carcinomas. (1) Radical neph-roureterectomy (RNU) has been [...]